These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 4199824)

  • 21. The specific prevention of measles in Romania. Study of a vaccine prepared in human diploid cells.
    Cepleanu M; Cajal N; Cernescu C; Sorodoc Y; Aderca I; Tigăeru N; Suciu D; Manu S; Ferra A; Biberimoroianu S; Dobrescu A; Lucian M
    Rev Roum Virol (1972); 1973; 10(1):8-17. PubMed ID: 4709858
    [No Abstract]   [Full Text] [Related]  

  • 22. [Measles vaccination programs in Western Africa].
    Foege WH
    Bol Oficina Sanit Panam; 1974 Dec; 77(6):500-8. PubMed ID: 4280917
    [No Abstract]   [Full Text] [Related]  

  • 23. [Experiment of vaccination against measles using attenuated virus (Schwarz strain) (author's transl)].
    Trivello R; Renzulli G; Romano M; Milone G; Moschen ME
    Ann Sclavo; 1978; 20(2):113-20. PubMed ID: 742926
    [No Abstract]   [Full Text] [Related]  

  • 24. Experience with live rubella virus vaccine combined with live vaccines against measles and mumps.
    Smorodintsev AA; Nasibov MN; Jakovleva NV
    Bull World Health Organ; 1970; 42(2):283-9. PubMed ID: 5310140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Specific anti-measles prophylaxis in Rumania. 3. Comparative study of some live attenuated virus vaccines].
    Cajal N; Cepleanu M; Cernescu C; Sorodoc Y
    Stud Cercet Inframicrobiol; 1969; 20(4):275-85. PubMed ID: 5371258
    [No Abstract]   [Full Text] [Related]  

  • 26. Studies on the modification of the live AIK measles vaccine. II. Development and evaluation of the live AIK-C measles vaccine.
    Makino S; Sasaki K; Nakamura N; Nakagawa M; Nakajima S
    Kitasato Arch Exp Med; 1974 Jun; 47(1-2):13-21. PubMed ID: 4476032
    [No Abstract]   [Full Text] [Related]  

  • 27. A comparative study of two live measles vaccines in Iran.
    Mirchamsy H; Shafyi A; Bassali Y; Bahrami S; Nazari F
    J Hyg (Lond); 1970 Mar; 68(1):101-10. PubMed ID: 5266577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative evaluation of two combined measles-mumps-rubella vaccines based on AIK and Edmonston- Zagreb strains of measles virus.
    Mirchamsy H; Nilforoushan MA; Shafyi A; Razavi J; Ashtiani MP; Youssofi I; Sassani A; Fateh G; Nassiri S
    Kitasato Arch Exp Med; 1991 Sep; 64(2-3):141-7. PubMed ID: 1811112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mass measles vaccination: experience with live attenuated virus vaccine in and around Vellore.
    Benjamin V; Jadhav M; Roberts PO
    Indian Pediatr; 1969 Mar; 6(3):102-13. PubMed ID: 5784931
    [No Abstract]   [Full Text] [Related]  

  • 30. Head-to-head immunogenicity comparison of Edmonston-Zagreb vs. AIK-C measles vaccine strains in infants aged 8-12 months: A randomized clinical trial.
    Izadi S; Zahraei SM; Salehi M; Mohammadi M; Tabatabaei SM; Mokhtari-Azad T
    Vaccine; 2018 Jan; 36(5):631-636. PubMed ID: 29289382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination against measles. Clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. Third report to the Medical Research Council by the Measles Vaccines Committee.
    Practitioner; 1971 Apr; 206(234):458-66. PubMed ID: 4930718
    [No Abstract]   [Full Text] [Related]  

  • 32. [Measles vaccination with split vaccines and living vaccines (author's transl)].
    Stehr K; Enders-Ruckle G; Spiess H
    MMW Munch Med Wochenschr; 1975 Jul; 117(27):1159-64. PubMed ID: 808710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of standard-titer AIK-C measles vaccine in nine-month-old infants.
    Tsai HY; Huang LM; Shih YT; Chen JM; Jiang TM; Tsai CH; Lee CY
    Viral Immunol; 1999; 12(4):343-8. PubMed ID: 10630793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [High-potency live attenuated measles virus vaccine. Clinical results of Schwarz vaccine].
    Fujii Y; Minamitani M; Nakamura K; Shinozaki T; Nagahama H
    Nihon Ishikai Zasshi; 1969 Mar; 61(5):595-601. PubMed ID: 4890864
    [No Abstract]   [Full Text] [Related]  

  • 35. [Trials of vaccination against measles with live and attenuated virus].
    Albano A; De Donato S; Nodari R; Criscuolo A
    G Mal Infett Parassit; 1967 Oct; 19(10):631-8. PubMed ID: 5611500
    [No Abstract]   [Full Text] [Related]  

  • 36. Differences in the appearance of antibodies to structural components of measles virus after immunization with inactivated and live virus.
    Norrby E; Enders-Ruckle G; Meulen V
    J Infect Dis; 1975 Sep; 132(3):262-9. PubMed ID: 1159329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination against measles: a neverending story.
    Stittelaar KJ; de Swart RL; Osterhaus AD
    Expert Rev Vaccines; 2002 Aug; 1(2):151-9. PubMed ID: 12901554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trial of a reduced dose of measles vaccine in Nigerian children.
    Wallace RB; Landrigan PJ; Smith EA; Pifer J; Teller B; Foster SO
    Bull World Health Organ; 1976; 53(4):361-4. PubMed ID: 1086728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.
    Asatryan A; Pool V; Chen RT; Kohl KS; Davis RL; Iskander JK;
    Vaccine; 2008 Feb; 26(9):1166-72. PubMed ID: 18255204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inactivated measles virus vaccine. Subsequent challenge with attenuated live virus vaccine.
    KARELITZ S; BERLINER BC; ORANGE M; PENBHARKKUL S; RAMOS A; MUENBOON P
    JAMA; 1963 Jun; 184():673-9. PubMed ID: 13962482
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.